Zhuo Li
Mayo Clinic
Internal medicineSurgeryOncologyCardiologyRetrospective cohort studyHazard ratioSurvival rateAortic valve replacementArteryMitral valveHeart failureCardiac surgeryAtrial fibrillationMitral valve repairAortic valveMitral regurgitationAnesthesiaIncidence (epidemiology)MedicineEjection fraction
Publications 152
#1Santo Maimone (Mayo Clinic)H-Index: 4
#2Andrey P Morozov (Mayo Clinic)H-Index: 1
Last. Sarah A. McLaughlin (Mayo Clinic)H-Index: 26
view all 6 authors...
OBJECTIVE Evaluate utilization of MRI-directed breast ultrasound (US) in patients with newly diagnosed breast cancer and refine practices to increase success of sonographic lesion detection. METHODS This retrospective single-institution review was restricted to women with breast cancer who underwent MRI from November 2006 to January 2017. Enhancing breast lesions, separate from the index tumor, recommended for MRI-directed US were assessed to see which were detected and which characteristics pre...
#1Ami GrekH-Index: 2
#2Emily R. RogersH-Index: 1
Last. Pablo Moreno FrancoH-Index: 8
view all 8 authors...
ABSTRACT Hospital 30-day readmissions remain a major quality and cost indicator. Traditional readmission risk scores, such as LACE (length of stay, acuity of admission, Charlson comorbidity index, and emergency department visits), may be suboptimal in special patient populations, such as those with sepsis. As sepsis survivorship improves, there is a need to determine which variables might be associated with a decrease in 30-day readmission. We completed a retrospective analysis reviewing patient...
#1Scott A. Helgeson (Mayo Clinic)H-Index: 4
#2Mark R. Waddle (Mayo Clinic)H-Index: 9
Last. Neal M. Patel (Mayo Clinic)H-Index: 4
view all 9 authors...
Objectives null Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are the most commonly prescribed antihypertensives, with prior studies identifying a possible association between long-term use and increased rates of lung cancer. This study evaluated this potential association in a large population using propensity matching. null Methods null This was a population-based cohort study in a large healthcare system in three regions of the United States. Pairwi...
#1Kristin A. Robinson (Mayo Clinic)H-Index: 7
#2Santo Maimone (Mayo Clinic)H-Index: 4
Last. Saranya Chumsri (Mayo Clinic)H-Index: 23
view all 6 authors...
#1Pooja Advani (Mayo Clinic)H-Index: 13
#2Saranya Chumsri (Mayo Clinic)H-Index: 23
Last. Ephraim E. Parent (Mayo Clinic)H-Index: 11
view all 6 authors...
Background null mRNA COVID-19 vaccines are known to provide an immune response seen on FDG PET studies. However, the time course of this metabolic response is unknown. We here present a temporal metabolic response to mRNA COVID-19 vaccination in oncology patients undergoing standard of care FDG PET. null Methods null 262 oncology patients undergoing standard of care FDG PET were included in the analysis. 231 patients had at least one dose of mRNA COVID-19 vaccine while 31 patients had not been v...
#1Ayah Istanbouli (Mayo Clinic)
#2Shreya Patel (Mayo Clinic)
Last. John A. Stauffer (Mayo Clinic)H-Index: 22
view all 5 authors...
BackgroundSurgical resection is the curative treatment for all subtypes of cholangiocarcinoma (CCA), including intrahepatic, hilar/peri-hilar, and distal. This study evaluates patients with CCA who...
#1Ephraim E. Parent (Mayo Clinic)H-Index: 11
#2Dhruv M Patel (Emory University)H-Index: 3
Last. Mark M. Goodman (Emory University)H-Index: 53
view all 7 authors...
Stereotactic radiosurgery (SRS) is often the primary treatment modality for patients with intracranial metastatic disease. Despite advances in magnetic resonance imaging, including use of perfusion and diffusion sequences and molecular imaging, distinguishing radiation necrosis from progressive tumor remains a diagnostic and clinical challenge. We investigated the sensitivity and specificity of 18F-fluciclovine PET to accurately distinguish radiation necrosis from recurrent intracranial metastat...
#2Nan SongH-Index: 9
Last. E. Aubrey Thompson (Mayo Clinic)H-Index: 38
view all 18 authors...
Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2+ breast cancer patients. NSABP investigators utilized gene expression profiles of N9831 patients (N = 892) to blindly assign patients to large-, moderate-, or no-trastuzumab benefit groups and then NCCTG investigat...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.